Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print   

Monday 11 January, 2021

Sensyne Health PLC

Notice of Interim Results

RNS Number : 1561L
Sensyne Health PLC
11 January 2021
 

 

 

 

Notice of Interim Results

 

Oxford, UK; 11 January 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company") , the Clinical AI company, will announce its Interim Results for the 6 months ended 31 October 2020 on Thursday 21 January 2021.

 

Lord (Paul) Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will host a virtual briefing for analysts and investors at 13:00 GMT on the day of the results.

 

Details of the webcast, and the presentation slides, will be available via the Company website. For more details please contact [email protected]

 

 

-ENDS-

 

 

For more information please contact:

 

Sensyne Health ( www.sensynehealth.com )

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

 

Michael Norris, Interim Chief Financial Officer

 

Dr Richard Pye, Chief Investment Officer

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

Dr Christopher Golden

 

James Steel

 

Oliver Jackson

 

Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma

 

Euan Brown

 

Consilium Strategic Communications

+44 (0) 7780600290

Mary-Jane Elliott

 

Sukaina Virji

 

Davide Salvi

 

 

 

 

 

 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORSFFFMSEFSEIF

a d v e r t i s e m e n t